METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Clinical trials for METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to boost immune attack on Hard-to-Treat head and neck cancer
Disease control OngoingThis study tests a combination of two drugs—cetuximab and interleukin-12—in people with advanced head and neck cancer that has returned, spread, or cannot be removed by surgery. The goal is to find the safest dose of interleukin-12 and see if the pair can shrink tumors by helping…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:22 UTC
-
New drug cocktail shows promise for hard-to-treat head and neck cancer
Disease control OngoingThis study tests a combination of three drugs (olaparib, pembrolizumab, and carboplatin) as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if this mix works better than the current standard therapy. About 30 adults with inc…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 26, 2026 04:20 UTC
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis study tests three different drug combinations in 430 people with advanced head and neck cancer that has spread or come back after immunotherapy stopped working. One group gets standard chemo plus cetuximab, another gets chemo plus bevacizumab, and a third gets bevacizumab pl…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:18 UTC
-
New drug combo shows promise in fighting tough head and neck cancers
Disease control OngoingThis study tests whether adding ramucirumab to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer that has come back or spread. The trial includes 37 adults whose tumors have a specific marker (PD-L1 positi…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 26, 2026 04:13 UTC
-
New combo shows promise for tough head and neck cancers
Disease control OngoingThis study tested a combination of two drugs—nab-paclitaxel (a chemotherapy) and nivolumab (an immunotherapy)—in 46 people with advanced head and neck cancer that had stopped responding to a prior immunotherapy. The goal was to see if the combo could shrink tumors or slow the dis…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of sonidegib combined with the immunotherapy pembrolizumab in people with advanced solid tumors that have spread. The goal is to see if this drug pair can shrink tumors or slow their growth. About 36 adults with cancers like m…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
Promising combo tackles tough head and neck cancers
Disease control OngoingThis study tests a combination of an immunotherapy drug (cemiplimab) and low-dose chemotherapy (paclitaxel and carboplatin) in 46 people with head and neck cancer that has returned or spread. The goal is to see if this mix can shrink tumors better than current treatments. Partici…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated May 19, 2026 11:52 UTC
-
New combo shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether adding the drug ipatasertib to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with head and neck cancer that has come back or spread. About 52 adults with incurable, advanced cancer will take part. The goal is to s…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New combo therapy shows promise for tough head and neck cancers
Disease control OngoingThis study tested a three-drug combination (sorafenib, carboplatin, and paclitaxel) in 48 people with head and neck cancer that had spread or returned. The goal was to see if the combination could shrink tumors or slow cancer growth. Researchers also looked at how long the benefi…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:01 UTC
-
Radiation boost may improve immunotherapy for advanced head and neck cancer
Disease control OngoingThis study compares two treatments for head and neck cancer that has spread to other parts of the body. All participants receive the immunotherapy drug pembrolizumab plus chemotherapy. Half also get targeted radiation to their tumors. The goal is to see if adding radiation helps …
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Fasting to fight cancer: new study tests eating windows for better immunotherapy results
Knowledge-focused TerminatedThis study was designed to see if limiting eating to a 10-hour window each day could help immunotherapy work better in people with advanced head and neck or kidney cancer. Researchers planned to compare outcomes in African American participants and others. The study was withdrawn…
Matched conditions: METASTATIC HEAD-AND-NECK SQUAMOUS-CELL CARCINOMA
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated May 26, 2026 03:57 UTC